Compare DOUG & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DOUG | IPHA |
|---|---|---|
| Founded | 1911 | 1999 |
| Country | United States | France |
| Employees | N/A | 163 |
| Industry | Building operators | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 162.3M | 189.5M |
| IPO Year | 2021 | N/A |
| Metric | DOUG | IPHA |
|---|---|---|
| Price | $1.82 | $1.91 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $5.75 |
| AVG Volume (30 Days) | ★ 471.4K | 128.4K |
| Earning Date | 05-05-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 118.68 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $955,578,000.00 | N/A |
| Revenue This Year | N/A | $180.36 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.53 | $1.18 |
| 52 Week High | $3.19 | $2.63 |
| Indicator | DOUG | IPHA |
|---|---|---|
| Relative Strength Index (RSI) | 48.97 | 54.47 |
| Support Level | $1.55 | $1.72 |
| Resistance Level | $1.84 | $2.34 |
| Average True Range (ATR) | 0.13 | 0.21 |
| MACD | -0.01 | 0.05 |
| Stochastic Oscillator | 40.98 | 40.77 |
Douglas Elliman Inc is engaged in the real estate services business and seeks to acquire or invest in additional real estate services businesses. The Company also offers, through its subsidiaries and ventures, development marketing services and ancillary services, including mortgage, title, and escrow services. It generates revenue from commissions and other brokerage income, property management, and other ancillary services.
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.